February 26, 2025 - 14:35
A federal judge in Washington has mandated CVS Health Corp. to comply with a document request from the U.S. Federal Trade Commission (FTC). This ruling marks a significant victory for the FTC in its ongoing battle against drug benefits middlemen, also known as pharmacy benefit managers (PBMs). The agency has been scrutinizing the practices of these intermediaries, which play a crucial role in determining drug prices and access for consumers.
The FTC's investigation into CVS and other PBMs aims to uncover potential anti-competitive behaviors that could be impacting drug pricing and availability. This legal decision underscores the growing concern about the influence of PBMs in the pharmaceutical industry and their effect on healthcare costs. The FTC has been actively working to ensure transparency and fairness in drug pricing, and this ruling is a crucial step in that direction. As CVS prepares to comply, the implications of this order could lead to broader changes in the practices of PBMs across the industry.
